Abcam, the Cambridge based online antibody supplier, reported in an update regarding the interim results to December 2011 that they are anticipated to show sales growth of 13.5% (2010: £39.4 million). Improved gross and operating margins have also been achieved through tight cost control and some exchange rate benefit.
The year end catalogue totalled 81,818 products (2010: 69,160). Trading remains on track to meet the board's full year expectations.
The ABC share price has increased by 4.4% over the past year.
Abcam Plc is graded B by LCF Research. To learn more, follow the link.
This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.